British Menopause Society. Urogenital atrophy consensus statement. 2021. (accessed 19 October 2022)

British Menopause Society. Practice standards. 2022. (accessed 19 October 2022)

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394:(10204)1159-1168

Davis SR, Baber RJ. Treating menopause - MHT and beyond. Nat Rev Endocrinol. 2022; 18:(8)490-502

Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?. Climacteric. 2016; 19:(2)151-161

Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric. 2013; 16:(2)205-213

Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med. 2013; 10:(6)1567-1574

Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016; 19:(2)188-197

National Institute for Health and Care Excellence. Menopause: diagnosis and management. NG 23. 2015. (accessed 19 October 2022)

Palacios S. Managing urogenital atrophy. Maturitas. 2009; 63:(4)315-318

Palacios S, Combalia J, Emsellem C, Gaslain Y, Khorsandi D. Therapies for the management of genitourinary syndrome of menopause. Post Reprod Health. 2020; 26:(1)32-42

Palacios S, Mejía A, Neyro JL. Treatment of the genitourinary syndrome of menopause. Climacteric. 2015; 18:23-29

Vaginal atrophy: what is it and how can it be treated?

02 November 2022
Volume 33 · Issue 11


Vaginal atrophy is common and can impact on quality of life for many women. Debra Holloway explores how the condition can be managed in primary care

Vaginal atrophy is a common, chronic and progressive condition that occurs due to oestrogen deficiency. It is an under-recognised condition that can have a negative impact on quality of life. Vaginal atrophy can be treated and the aims of treatment are to promote comfort and ensure that symptoms are reduced. Practice nurses need to be comfortable asking sensitive questions and be able to give advice and signpost women to relevant and up to date information.

Vaginal atrophy is a common condition for women in the menopause. It is chronic and progressive and will not get better without treatment over time, unlike vasomotor symptoms (Palacios et al, 2020). Vaginal atrophy is a condition in a larger spectrum known as genital syndrome of the menopause (GSM), which incorporates physical changes in the vulva, vagina and lower urinary tract. All of the above structures have oestrogen and androgen receptors and as the oestrogen level decreases several effects are observed as shown in Table 1.

It is estimated that vaginal atrophy affects 50–80% of post-menopausal women and is caused by oestrogen deficiency (Palacios et al, 2020; Davis and Baber, 2022), but it is an under-diagnosed and under-recognised condition. This is due to many factors such as:

Vaginal atrophy and lack of lubrication can also occur at any time in a woman's life and this happens in an estimated 15% of pre-menopausal women, when they are breast feeding, have hypothalamic amenorrhoea, are on the combined oral contraceptive pill, with stress, after chemotherapy and pelvic radiation, and with certain chronic conditions (Edwards and Panay, 2016).

Register now to continue reading

Thank you for visiting Practice Nursing and reading some of our peer-reviewed resources for general practice nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month